Celltrion Files Stelara Biosimilar In US And Canada

Korean Firm Submits CT-P43 Ustekinumab Candidate To US FDA And Health Canada

 
• By Dave Wallace

Celltrion has filed its CT-P43 proposed ustekinumab biosimilar rival to Stelara with the US Food and Drug Administration and Health Canada.

US and Canadian flags
Celltrion has submitted its ustekinumab biosimilar in North America • Source: Shutterstock

More from Biosimilars

More from Products